Table 3 Overall Response Rates according to the investigators
Best response | Investigator assessment N (%) |
|---|---|
Complete response | 2 (2.0%) |
Partial response | 23 (22.5%) |
Stable disease | 42 (41.2%) |
Progressive disease | 31 (30.4%) |
Not evaluable | 4 (3.9%) |
Overall tumor response rate (CR + PR) | 25 (24.5%) |
Clinical benefit rate (CR + PR + SD) | 67 (65.7%) |